IMMUCELL CORP /DE/ICCCEarnings & Financial Report
Nasdaq
NextMar 28, 2026
ICCC Q3 2025 Key Financial Metrics
Revenue
$5.5M
Gross Profit
$2.4M
Operating Profit
$20.1K
Net Profit
$-139.7K
Gross Margin
42.9%
Operating Margin
0.4%
Net Margin
-2.5%
YoY Growth
-8.4%
EPS
$-0.02
Financial Flow
IMMUCELL CORP /DE/ Q3 2025 Financial Summary
IMMUCELL CORP /DE/ reported revenue of $5.5M for Q3 2025, with a net profit of $-139.7K (-2.5% margin). Cost of goods sold was $3.1M, operating expenses totaled $2.3M.
Key Financial Metrics
| Total Revenue | $5.5M |
|---|---|
| Net Profit | $-139.7K |
| Gross Margin | 42.9% |
| Operating Margin | 0.4% |
| Report Period | Q3 2025 |
IMMUCELL CORP /DE/ Annual Revenue by Year
IMMUCELL CORP /DE/ annual revenue history includes year-by-year totals (for example, 2024 revenue was $26.5M).
| Year | Annual Revenue |
|---|---|
| 2024 | $26.5M |
| 2023 | $17.5M |
| 2022 | $18.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.1M | $7.3M | $5.5M | $6.0M | $7.8M | $8.1M | $6.4M | $5.5M |
| YoY Growth | 30.3% | 110.6% | 54.9% | 11.4% | 52.1% | 11.2% | 17.8% | -8.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $43.8M | $43.1M | $41.9M | $44.4M | $45.1M | $45.6M | $46.7M | $45.7M |
| Liabilities | $18.8M | $18.4M | $18.4M | $18.0M | $17.6M | $16.6M | $16.9M | $15.9M |
| Equity | $25.0M | $24.6M | $23.5M | $26.4M | $27.5M | $29.0M | $29.9M | $29.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-723071 | $418505 | $581780 | $-639331 | $-3051 | $1.6M | $1.6M | $-1.2M |